Skip to main content

Advertisement

SpringerLink
Log in

FGF-23 levels in patients with critical carotid artery stenosis

  • IM - ORIGINAL
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate fibroblast growth factor (FGF)-23 serum levels and its tissue expression in patients with critical carotid artery stenosis (CAS). We selected 35 patients with critical CAS undergoing carotid thromboendoarterectomy. In each patient, FGF-23 serum levels were evaluated just prior to the surgery (t0) and 30 min (t1) thereafter. Moreover, macrophage cytokines were measured at baselines. Carotid artery specimens were used for immune histochemistry. On the basis of the histology, the patients were divided into 2 groups: A with complicated plaque and B with uncomplicated plaque. Twenty complicated plaques (57.14 %, group A,) and 15 uncomplicated (42.86 %, group B) were evaluated: calcifications were present in 16/20 (80 %) complicated plaques and in 6/15 (40 %) uncomplicated plaques. An inflammatory infiltrate was observed in 26/35 carotid samples: 18/26 (69.23 %) complicated and 8/26 (30.76 %) uncomplicated. FGF-23+ cells were present in 17/20 complicated (85 %) and in 8 uncomplicated (53 %) plaques. The double-staining immunofluorescence confirmed that macrophage cells (CD68+) were also positive for FGF-23 staining. Serum levels of FGF-23 were significantly higher in group A versus group B at t0 (p < 0.05) and t1 (p 0.0047). Moreover, in group A patients a significant increase of FGF-23 serum levels was observed at t1 in comparison with t0 (p 0.0011). Our results suggest that FGF-23 acts in the late phases of atherosclerotic disease and may potentially represent a marker of complications in critical CAS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Riminucci M, Collins MT, Fedarko NS et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Shimada T, Hasegawa H, Yamazaki Y et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435

    Article  CAS  PubMed  Google Scholar 

  3. Goldsmith DJ, Cunningham J (2011) Mineral metabolism and vitamin D in chronic kidney disease–more questions than answers. Nat Rev Neprhol 7:341–346

    Article  CAS  Google Scholar 

  4. Moe SM, Chen NX (2008) Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19(2):213–216

    Article  CAS  PubMed  Google Scholar 

  5. Isakova T, Xie H, Yang W et al (2011) FGF-23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Gutierrez OM, Mannstadt M, Isakova T et al (2008) FGF-23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Gutierrez OM, Januzzi JL, Isakova T et al (2009) FGF-23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. NasrAllah MM, El-SheHaby AR, Osman NA et al (2013) The association between fibroblast growth factor-23 and vascular calcification is mitigated by inflammation markers. Nephron Extra 3:106–112

    Article  PubMed Central  PubMed  Google Scholar 

  9. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE (2009) Circulating FGF-23 is associated with vascular dysfunction in the community. Atherosclerosis 205:385–390

    Article  CAS  PubMed  Google Scholar 

  10. Arnlov J, Lind L, Larsson Tobias E (2013) Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 83:160–166

    Article  PubMed  Google Scholar 

  11. Mirza MA, Hansen T, Johansson L et al (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 205:385–390

    CAS  Google Scholar 

  12. Raman G, Moorthy D, Hadar N et al (2013) Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med 158:676–685

    Article  PubMed  Google Scholar 

  13. Stary HC, Chandler AB, Dinsmore RE et al (1995) A definition of advanced type of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92:1355–1374

    Article  CAS  PubMed  Google Scholar 

  14. Hansson GK (2005) Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352:1685–1695

    Article  CAS  PubMed  Google Scholar 

  15. Mendoza JM, Isakova T, Ricardo AC et al (2012) Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 7:1155–1162

    Article  CAS  Google Scholar 

  16. Del Porto F, Proietta M, Tritapepe L et al (2010) Inflammation and immune response in acute aortic dissection. Ann Med 42:622–629

    Article  PubMed  Google Scholar 

  17. Lindeman JH, Abdul-Hussein H, Schaapherder AF et al (2008) Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6 and IL-8 dominated inflammatory responses prevail in the human aneurysms. Clin Sci (London) 114:687–697

    Article  CAS  Google Scholar 

  18. Proietta M, Tritapepe L, Cifani N, Ferri L, Taurino M, Del Porto F (2014) MMP-12 as a new marker of Stanford-A acute aortic dissection. Ann Med 46:44–48

    Article  CAS  PubMed  Google Scholar 

  19. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610–621

    Article  CAS  PubMed  Google Scholar 

  20. Benagiano M, Munari F, Ciervo A et al (2012) Chlamydophila pneumonia phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. PNAS 109:1222–1227

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Liu ZD, Wang L, Lu FH et al (2012) Increased Th17 cell frequency concomitant with decreased Foxp3 + Treg cell frequency in the peripheral circulation of patients with carotid artery plaques. Inflamm Res 61(10):1155–1165

    Article  CAS  PubMed  Google Scholar 

  22. Ozkok A, Kekik C, Karahan GE et al (2013) FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrology 14:241–248

    Article  PubMed Central  PubMed  Google Scholar 

  23. Masai H, Joki N, Sugi K, Moroi M (2013) A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease. Atherosclerosis 226:228–233

    Article  CAS  PubMed  Google Scholar 

  24. Scialla JJ, Lau WL, Reilly MP et al (2013) Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83:1159–1168

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Balci M, Kirkpantur A, Gulbay M et al (2010) Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int 14:425–432

    Article  PubMed  Google Scholar 

  26. Asicioglu E, Kahveci H, Arikan H, Koc M, Tuglular S, Ozener C (2014) Fibroblast growth factor-23 levels are associated with uric acid but not carotid intima media thickness in renal transplant recipients. Transplant Proc 46:180

    Article  CAS  PubMed  Google Scholar 

  27. Kestenbaum B, Sachs MC, Hoofnagle AN (2014) Fibroblast growth factor-23 and cardiovascular disease in the general population. Circ Heart Fail 2014(7):409

    Article  Google Scholar 

  28. Wu B, Pei X, Li ZY (2014) How does calcification influence plaque vulnerability? Insights from fatigue analysis. Sci World J 2014:417324. doi:10.1155/2014/417324

Download references

Acknowledgments

This study was funded by the Università di Roma “La Sapienza”, Progetto di Ricerca di Università Anno: 2010-prot. C26A10ETWL

Conflict of interest

The authors have no conflict of interest to declare, including specific financial interest or relationship with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include employment by any industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors or being publicly associated with the company of its products. Moreover, the authors declare that they have not received honoraria, fees, grants or funds from such corporations or individuals representing such corporations.

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Clinica e Molecolare, Facoltà di Medicina e Psicologia, UOC Medicina 3, Azienda Ospedaliera Sant’Andrea, Università “La Sapienza”, Rome, Italy

    Flavia Del Porto, Maria Proietta, Noemi Cifani & Livia Ferri

  2. Dipartimento di Scienze Radiologiche, Oncologiche ed Anatomopatologiche, Facoltà di Medicina e Odontoiatria, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy

    Cira di Gioia & Lucrezia Fabriani

  3. Dipartimento di Medicina Clinica e Molecolare, Facoltà di Medicina e Psicologia, UOC chirurgia Vascolare, Ospedale Sant’Andrea, Sapienza Università di Roma, Rome, Italy

    Raffaele Dito, Cristiano Fantozzi & Maurizio Taurino

  4. Dipartimento di Scienze Medico-Chirurgiche e Medicina Traslazionale, UOC Medicina 3, Ospedale Sant’Andrea, Sapienza Università di Roma, Rome, Italy

    Michele Rossi

  5. Dipartimento di Scienze Anestesiologiche, Medicina Critica e Terapia del Dolore, Facoltà di Medicina e Odontoiatria, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy

    Luigi Tritapepe

Authors
  1. Flavia Del Porto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Proietta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cira di Gioia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noemi Cifani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raffaele Dito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cristiano Fantozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Livia Ferri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lucrezia Fabriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michele Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Luigi Tritapepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Maurizio Taurino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Flavia Del Porto.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Del Porto, F., Proietta, M., di Gioia, C. et al. FGF-23 levels in patients with critical carotid artery stenosis. Intern Emerg Med 10, 437–444 (2015). https://doi.org/10.1007/s11739-014-1183-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-014-1183-3

Keywords

Search

Navigation